Overview

Data as of October 05, 2021 06:31 am EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Summary Toggle Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

October 04, 2021

In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH CONSHOHOCKEN, Pa. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel
Summary Toggle Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update

August 05, 2021

CONSHOHOCKEN, Pa. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments. Paul Friedman , M.D., Chief Executive Officer of Madrigal, stated, “The Madrigal team has
Summary Toggle Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer

August 02, 2021

CONSHOHOCKEN, Pa. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals , a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr.

Filing date	Form	Description	Filing Group	View
July 05, 2017	D		Other	0001288452-17-000002.rtf 0001288452-17-000002.pdf
December 12, 2019	424B7	424B7	Registration Statements	0001193125-19-312878.rtf 0001193125-19-312878.xls 0001193125-19-312878.pdf
April 17, 2013	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	0001047469-13-004491.rtf 0001047469-13-004491.xls 0001047469-13-004491.pdf